Disis L Mary

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  2. pmc SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery
    Davide Bedognetti
    Society for Immunotherapy of Cancer, Milwaukee, WI, USA
    J Transl Med 9:155. 2011
  3. pmc A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008
  4. pmc Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology
    Hideaki Tahara
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    J Transl Med 7:45. 2009
  5. pmc Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses
    Vivian Goodell
    Center for Translational Medicine in Women s Health, 2nd Floor, 815 Mercer Street, Box 358050, University of Washington, Seattle, WA 98109 USA
    BMC Immunol 8:21. 2007
  6. pmc Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT
    Holden T Maecker
    BD Biosciences, San Jose, USA
    BMC Immunol 6:17. 2005
  7. pmc His-tag ELISA for the detection of humoral tumor-specific immunity
    Vivian Goodell
    Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98109 8050, USA
    BMC Immunol 9:23. 2008
  8. pmc The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer
    Tobias Hahn
    Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR 97213, USA
    BMC Cancer 11:471. 2011
  9. pmc Antimetastatic gene expression profiles mediated by retinoic acid receptor beta 2 in MDA-MB-435 breast cancer cells
    Brett Wallden
    Department of Pathology, University of Washington, Box 357470, Seattle, WA, USA
    BMC Cancer 5:140. 2005
  10. ncbi request reprint Future directions in the management of ovarian cancer
    Mary L Disis
    Department of Oncology, University of Washington, Box 356527, Seattle, WA 98195 6527, USA
    Hematol Oncol Clin North Am 17:1075-85. 2003

Detail Information

Publications89

  1. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  2. pmc SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery
    Davide Bedognetti
    Society for Immunotherapy of Cancer, Milwaukee, WI, USA
    J Transl Med 9:155. 2011
    ..This organized collection of the most useful references, online resources and tools serves as a compass to guide discovery of biomarkers essential to advancing novel cancer immunotherapies...
  3. pmc A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008
    ..This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document...
  4. pmc Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology
    Hideaki Tahara
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    J Transl Med 7:45. 2009
    ..The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions...
  5. pmc Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses
    Vivian Goodell
    Center for Translational Medicine in Women s Health, 2nd Floor, 815 Mercer Street, Box 358050, University of Washington, Seattle, WA 98109 USA
    BMC Immunol 8:21. 2007
    ..Samples from 27 Stage II, III, and IV HER-2/neu positive breast cancer patients, vaccinated against the HER-2/neu protein and tt, were analyzed by tritiated thymidine incorporation and IFN-gamma ELISPOT for T cell response...
  6. pmc Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT
    Holden T Maecker
    BD Biosciences, San Jose, USA
    BMC Immunol 6:17. 2005
    ..In this study, we compared the performance of these assays on leukapheresed PBMC shipped overnight in medium versus cryopreserved PBMC from matched donors...
  7. pmc His-tag ELISA for the detection of humoral tumor-specific immunity
    Vivian Goodell
    Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98109 8050, USA
    BMC Immunol 9:23. 2008
    ....
  8. pmc The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer
    Tobias Hahn
    Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR 97213, USA
    BMC Cancer 11:471. 2011
    ....
  9. pmc Antimetastatic gene expression profiles mediated by retinoic acid receptor beta 2 in MDA-MB-435 breast cancer cells
    Brett Wallden
    Department of Pathology, University of Washington, Box 357470, Seattle, WA, USA
    BMC Cancer 5:140. 2005
    ..We investigated both cultured cells and xenograft tumors in order to delineate the gene expression profiles responsible for an antimetastatic phenotype...
  10. ncbi request reprint Future directions in the management of ovarian cancer
    Mary L Disis
    Department of Oncology, University of Washington, Box 356527, Seattle, WA 98195 6527, USA
    Hematol Oncol Clin North Am 17:1075-85. 2003
    ....
  11. ncbi request reprint Clinical use of subcutaneous G-CSF or GM-CSF in malignancy
    Mary L Disis
    Center for Translational Medicine in Women s Health, University of Washington, Seattle, Washington 91809, USA
    Oncology (Williston Park) 19:5-9. 2005
  12. ncbi request reprint Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity
    Mary L Disis
    Tumor Vaccine Group, Division of Oncology, University of Washington, Seattle, WA 98195 6527, USA
    Mol Cancer Ther 2:995-1002. 2003
    ..DNA vaccines encoding neu, when given in combination with both CD137L and either CD80 or CD86, can induce cellular and humoral immunity and result in an antitumor effect...
  13. ncbi request reprint Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients
    Mary L Disis
    Tumor Vaccine Group, Division of Oncology, University of Washington, Seattle, Washington 98195 6527, USA
    J Clin Immunol 24:571-8. 2004
    ..Intermolecular epitope-spreading to p53 was evident in 20% of vaccinated patients. Of those patients who developed new immunity to p53, 71% had demonstrated antibody epitope-spreading within HER-2/neu...
  14. ncbi request reprint HER-2/neu vaccines
    Mary L Disis
    University of Washington, Seattle 98195 6527, USA
    Cancer Chemother Biol Response Modif 21:275-85. 2003
  15. ncbi request reprint Maximizing the retention of antigen specific lymphocyte function after cryopreservation
    Mary L Disis
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, 815 Mercer Street, 2nd Floor, Box 358050, University of Washington, Seattle, WA 98195 8050, USA
    J Immunol Methods 308:13-8. 2006
    ..I.) of the non-cryopreserved PBMC and SI obtained from cells frozen with media containing human serum albumin as compared to other additives such as dextran or fetal bovine serum...
  16. ncbi request reprint Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine
    Mary L Disis
    Tumor Vaccine Group, Oncology, University of Washington, Seattle, WA 98195 6527, USA
    J Clin Oncol 22:1916-25. 2004
    ..To evaluate the safety of an HER-2/neu intracellular domain (ICD) protein vaccine and to estimate whether vaccine dose impacts immunogenicity...
  17. ncbi request reprint Peptide-based vaccines in breast cancer
    Mary L Disis
    Tumor Vaccine Group, Oncology, University of Washington, Seattle, WA 98195 6527, USA
    Breast Dis 20:3-11. 2004
    ..Peptide based vaccines are one of the most commonly studied vaccine strategies targeting breast cancer...
  18. ncbi request reprint Progress in ovarian cancer research: proceedings of the 5th Biennial Ovarian Cancer Research Symposium
    M L Disis
    University of Washington, Seattle, Washington, USA
    Int J Gynecol Cancer 16:463-9. 2006
    ..The need for strategies that would optimize patient participation in clinical trials is paramount...
  19. ncbi request reprint Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens
    Mary L Disis
    Division of Oncology, University of Washington, Seattle, Washington 98195 6527, USA
    Immunobiology 207:179-86. 2003
    ..Antibodies directed against rat neu were not elicited with this approach, indicating that the neu specific T cell immune response elicited with plasmid DNA was skewed towards cell-mediated rather than humoral immunity...
  20. ncbi request reprint High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer
    M L Disis
    Department of Medicine, University of Washington, Seattle 98195 6527, USA
    J Clin Oncol 15:3363-7. 1997
    ....
  21. ncbi request reprint Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
    M L Disis
    Division of Oncology, University of Washington, Seattle 98195 6527, USA
    Clin Cancer Res 5:1289-97. 1999
    ..The use of peptide-based vaccines may be a simple, yet effective, vaccine strategy for immunizing humans to oncogenic self-proteins...
  22. ncbi request reprint Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization
    M L Disis
    Division of Oncology, University of Washington, Seattle 98195, USA
    Clin Cancer Res 6:1347-50. 2000
    ....
  23. ncbi request reprint Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer
    M L Disis
    Division of Oncology, University of Washington, Seattle 98195 6527, USA
    Breast Cancer Res Treat 62:245-52. 2000
    ..However, in the case of the HER-2/neu antigen, the pre-existent tumor specific immune response is found only in a minority of patients...
  24. ncbi request reprint Clinical translation of peptide-based vaccine trials: the HER-2/neu model
    M L Disis
    Division of Oncology, University of Washington, Seattle 98195 6527, USA
    Crit Rev Immunol 21:263-73. 2001
    ..with little distress and risk to the patients enrolled in the study? Finally, what steps must be implemented for a laboratory assay to evolve to meet the validation criteria needed for application as an immunologic monitoring tool?..
  25. ncbi request reprint Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers
    Mary L Disis
    Division of Oncology, University of Washington, Seattle, WA 98195 6527, USA
    Blood 99:2845-50. 2002
    ..Finally, vaccine regimens including FL as a vaccine adjuvant were associated with the development of apparent autoimmune phenomena in some patients...
  26. ncbi request reprint Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines
    Mary L Disis
    Division of Oncology and Department of Dermatology, University of Washington, Seattle 98195 6527, USA
    J Clin Oncol 20:2624-32. 2002
    ....
  27. doi request reprint Immunologic biomarkers as correlates of clinical response to cancer immunotherapy
    Mary L Disis
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, 815 Mercer Street, 2nd Floor, Box 358050, Seattle, WA 98195 8050, USA
    Cancer Immunol Immunother 60:433-42. 2011
    ....
  28. pmc Immunomodulation of breast cancer via tumor antigen specific Th1
    Mary L Disis
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98195 8050, USA
    Cancer Res Treat 41:117-21. 2009
    ..Clinical trials of a variety of immunotherapeutic strategies indicate that the generation of tumor antigen specific Th1 may be beneficial in inhibiting the growth of common solid tumors...
  29. pmc Immune regulation of cancer
    Mary L Disis
    Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98109, USA
    J Clin Oncol 28:4531-8. 2010
    ..Immune-based therapies have the potential to modulate the tumor microenvironment by eliciting immune system cells that will initiate acute inflammation that leads to tissue destruction...
  30. doi request reprint The road we must take: multidisciplinary team science
    Mary L Disis
    School of Medicine, University of Washington, Seattle, WA 98195, USA
    Sci Transl Med 2:22cm9. 2010
    ..Critically needed, however, is an emphasis on creating and sustaining multidisciplinary research teams. It is through the power of many and a diverse approach to our health care problems that we will realize lasting solutions...
  31. doi request reprint The ultimate in cancer chemoprevention: cancer vaccines
    Mary L Disis
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, 815 Mercer Street, University of Washington, Seattle, WA 98195 8050, USA
    Cancer Prev Res (Phila) 3:406-9. 2010
    ..The ability to develop effective cancer vaccines for prevention is fast becoming a reality as immunogenic aberrant proteins that drive malignant transformation are identified...
  32. doi request reprint Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment
    Mary L Disis
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, Washington 98195 8050, USA
    Clin Cancer Res 15:6476-8. 2009
    ..Transforming growth factor beta (TGFbeta) actively modulates both inflammation and tolerance induction. Combining vaccination with agents that disarm TGFbeta will enhance vaccine efficacy...
  33. pmc Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer
    Mary L Disis
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98195 8050, USA
    J Clin Oncol 27:4685-92. 2009
    ....
  34. ncbi request reprint Oncogenic proteins as tumor antigens
    M L Disis
    University of Washington, Division of Oncology, Seattle 98195 6527, USA
    Curr Opin Immunol 8:637-42. 1996
    ..Immune system based treatments targeting oncogenic proteins have shown therapeutic efficacy in animals models and are currently being translated into human clinical trials...
  35. ncbi request reprint Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion
    Hongtao Zhang
    Department of Pathology, Center for Translational Medicine in Women s Health, University of Washington, Seattle, USA
    Mol Cancer Ther 5:149-55. 2006
    ..In contrast, repeated administration of either of two different anti-CD137 monoclonal antibodies did not induce complete tumor regression, although tumor growth was delayed...
  36. pmc Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation
    Leisha A Emens
    Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Clin Oncol 27:5911-8. 2009
    ..We tested the hypothesis that cyclophosphamide (CY) and doxorubicin (DOX) can enhance vaccine-induced immunity in patients with breast cancer...
  37. pmc HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase
    Brian M Olson
    Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    Cancer Immunol Immunother 59:943-53. 2010
    ..In addition, we propose that the epitopes identified here could be used to monitor immune responses in HLA-A2+ patients receiving vaccines targeting PAP to identify potentially therapeutic immune responses...
  38. ncbi request reprint Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells
    Junbao Yang
    Benaroya Research Institute at Virginia Mason, Seattle, WA, USA
    J Clin Immunol 25:428-36. 2005
    ..The availability of HLA-DP0401 tetramers should facilitate the study of DP restricted T cell responses...
  39. ncbi request reprint Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor
    Jon Ladd
    Department of Chemical Engineering, University of Washington, Seattle, Washington 98195, USA
    Colloids Surf B Biointerfaces 70:1-6. 2009
    ..Three serum samples from cancer patients with positive CEA antibody levels as evaluated by ELISA were used to test the criterion...
  40. ncbi request reprint Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant
    Douglas G McNeel
    Department of Medicine, Section of Medical Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    J Clin Immunol 23:62-72. 2003
    ....
  41. ncbi request reprint Adoptive T-cell therapy for the treatment of solid tumours
    Keith L Knutson
    Division of Oncology, University of Washington, 1959 NE Pacific Street, HSB BB1321, Box 356527, Seattle, WA 98195 6527, USA
    Expert Opin Biol Ther 2:55-66. 2002
    ..In addition, advanced imaging techniques, such as positron emission tomography (PET), are being implemented in order to better define the in vivo function of ex vivo expanded tumour-specific T-cells...
  42. ncbi request reprint Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer
    Hailing Lu
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, 815 Mercer Street, Room 219, Seattle, WA, USA
    Expert Opin Ther Targets 11:235-44. 2007
    ..High-throughput methods to identify new serum antibodies for cancer diagnosis are also reviewed...
  43. ncbi request reprint Immunologic principles and immunotherapeutic approaches in ovarian cancer
    Keith L Knutson
    Tumor Vaccine Group, 1959 Northeast Pacific Street, Box 356527, HSB BB1321, University of Washington, Seattle, WA 98195, USA
    Hematol Oncol Clin North Am 17:1051-73. 2003
    ..It is hoped that discoveries at the bench along with lessons learned in prior clinical trials soon will allow clinicians to develop rationally based immunologic strategies to treat and prevent ovarian cancer...
  44. ncbi request reprint Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming
    Yushe Dang
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98109, USA
    Clin Cancer Res 13:1883-91. 2007
    ..In this study, we evaluated the feasibility of expanding HER-2/neu-specific T cells derived from peripheral blood ex vivo following in vivo priming with a HER-2/neu peptide vaccine...
  45. ncbi request reprint Tumor stromal barriers to the success of adoptive T cell therapy
    Vy Phan
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, Department of Medicine, University of Washington, 815 Mercer Street, Room 219, Seattle, WA 98109, USA
    Cancer Immunol Immunother 57:281-3. 2008
  46. doi request reprint Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer
    Hailing Lu
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, Washington 98109, USA
    J Proteome Res 7:1388-94. 2008
    ..The endogenous humoral immune response present in cancer patients may allow the identification of individuals exposed to the malignant transformation of somatic cells...
  47. pmc Use of tumour-responsive T cells as cancer treatment
    Mary L Disis
    Center for Translational Medicine in Women s Health, Tumor Vaccine Group, University of Washington, Seattle, WA, USA
    Lancet 373:673-83. 2009
    ..The future of T-cell immunity stimulation to treat cancer will need combination approaches focused on both the tumour and the T cell...
  48. ncbi request reprint Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers
    Lupe G Salazar
    Tumor Vaccine Group, Division of Oncology, University of Washington, Seattle 98109, USA
    Clin Immunol 125:275-80. 2007
    ..Additionally, the presence of tumor antigen-specific immunity prior to vaccination is associated with greater magnitude immune responses...
  49. ncbi request reprint Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice
    Keith L Knutson
    University of Washington, Tumor Vaccine Group, Department of Oncology, Seattle, Washington, USA
    Cancer Res 64:1146-51. 2004
    ....
  50. doi request reprint Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity
    Andrew L Coveler
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, 815 Mercer Street, Box 358050, Seattle, WA 98109, USA
    Breast Cancer Res Treat 113:95-100. 2009
    ..1). This is the first report to show that the use of trastuzumab, bisphosphonates and hormonal therapy concurrent with cancer vaccine administration have no impact on either the generation or the magnitude of vaccine induced immunity...
  51. ncbi request reprint The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens
    Hailing Lu
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98195, USA
    Cancer Res 66:9754-61. 2006
    ..Our results indicate that neu-tg mice bearing spontaneous tumors develop humoral immunity to their tumors similar to cancer patients and that tumor antigens identified in transgenic mouse may predict immunogenic human homologues...
  52. ncbi request reprint Immunotherapy for breast cancer
    Keith L Knutson
    Tumor Vaccine Group, University of Washington, Seattle, WA, USA
    Cancer Chemother Biol Response Modif 20:351-69. 2002
  53. ncbi request reprint Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity
    Keith L Knutson
    Division of Oncology, University of Washington, Seattle 98195 6527, USA
    Clin Cancer Res 8:1014-8. 2002
    ..However, the magnitude of the responses were low, as well as short-lived, suggesting that CD4+ T-cell help is required for lasting immunity to this epitope...
  54. ncbi request reprint Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient
    Keith L Knutson
    Division of Oncology, Department of Medicine, University of Washington, Seattle, WA 98195 6527, USA
    Hum Immunol 63:547-57. 2002
    ..These results suggest that a tumor antigen TCR, directed against a specific epitope, can be markedly polyclonal at multiple levels including CD4/CD8 and TCR...
  55. ncbi request reprint Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity
    Vivian Goodell
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98195 8050, United States
    J Immunol Methods 299:129-38. 2005
    ..Cell-based ELISA can be developed to be Clinical Laboratory Improvement Act (CLIA)-compliant and the flexibility of the approach will allow adaptation of the assay to multiple tumor antigen systems...
  56. ncbi request reprint Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients
    Kathy Schiffman
    Tumor Vaccine Group, University of Washington, Seattle 98195 6527, USA
    Breast Cancer Res Treat 74:17-23. 2002
    ..Moreover, a negative response by DTH testing to a battery of common recall antigens was not a reflection of the breast cancer patient's ability to mount a cell-mediated immune response to a vaccinated antigen, tt...
  57. ncbi request reprint Immune modulation as a therapeutic strategy for non-small-cell lung cancer
    Gregory E Holt
    Division of Pulmonary Critical Care Medicine, University of Washington, Seattle, WA 98109, USA
    Clin Lung Cancer 9:S13-9. 2008
    ..With continued work in this field, active immunotherapy may provide the necessary therapy for the successful treatment of this common disease...
  58. ncbi request reprint Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer
    Vivian Goodell
    Center for Translational Medicine in Women s Health, Tumor Vaccine Group, University of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Clin Oncol 24:762-8. 2006
    ..We questioned whether antibody immunity specific for ovarian cancer tumor antigens would predict disease outcome. We evaluated humoral immune responses against ovarian cancer antigens p53, HER-2/neu, and topoisomerase IIalpha...
  59. doi request reprint Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade
    Hailing Lu
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, 815 Mercer Street, Room 220, Box 358050, University of Washington, Seattle, WA 98195, USA
    J Immunol 184:5360-7. 2010
    ..These data suggest that the excessive inflammation induced by TLR agonists may result in a self-regulatory immunosuppression via IL-10 induction and that blocking IL-10 could enhance the therapeutic efficacy of these agents...
  60. ncbi request reprint Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase
    R Bruce Montgomery
    Division of Oncology, Department of Medicine, VA Puget Sound HCS University of Washington, Seattle, WA 98108, USA
    Cancer Res 65:650-6. 2005
    ..Endogenous anti-HER2 antibodies can effectively suppress HER2 kinase activity and downstream signaling to inhibit the transformed phenotype of HER2-expressing tumor cells...
  61. ncbi request reprint Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles
    Lupe G Salazar
    Tumor Vaccine Group, Division of Oncology, University of Washington, Seattle, Washington, USA
    Clin Cancer Res 9:5559-65. 2003
    ..Furthermore, we questioned whether MHC binding affinity could predict the in vivo immunogenicity of the HER-2/neu helper peptides...
  62. doi request reprint Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer
    Yushe Dang
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98109, USA
    Ann N Y Acad Sci 1174:81-7. 2009
    ..Most likely the clinical effectiveness of immune-based treatments will be predicted by panels of markers rather than single assays of a specific immune effector cell...
  63. doi request reprint Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity
    Vivian Goodell
    Tumor Vaccine Group, University of Washington, Seattle, WA 98109 8050, USA
    Mol Cancer Ther 7:449-54. 2008
    ..Overexpression of a self-tumor-associated protein is a potential mechanism by which immunogenicity is enhanced and may aid in the identification of biologically relevant proteins to target for immune-based molecular cancer therapies...
  64. doi request reprint Translational Research Working Group developmental pathway for immune response modifiers
    Martin A Cheever
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Clin Cancer Res 14:5692-9. 2008
    ..This paper discusses key challenges associated with the immune response modifier agent development process in light of the pathway...
  65. ncbi request reprint Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia
    Amy S Ginsburg
    Department of Internal Medicine, University of Washington, Seattle 98195, USA
    Am J Hematol 72:204-8. 2003
    ..cereus. This case demonstrates that, in the neutropenic patient with gastrointestinal complaints or in the setting of resolving neutropenic enterocolitis, it is important to anticipate possible B. cereus infection and sepsis...
  66. pmc Chitosan-alginate 3D scaffolds as a mimic of the glioma tumor microenvironment
    Forrest M Kievit
    Department of Materials Science and Engineering, University of Washington, Seattle, WA 98195, USA
    Biomaterials 31:5903-10. 2010
    ..This unique CA scaffold platform may offer a valuable alternative strategy to the time-consuming and costly animal studies for a wide variety of experimental designs...
  67. ncbi request reprint Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
    Tyler J Curiel
    Tulane University Health Science Center, New Orleans, Louisiana 70112, USA
    Nat Med 10:942-9. 2004
    ..This specific recruitment of T(reg) cells represents a mechanism by which tumors may foster immune privilege. Thus, blocking T(reg) cell migration or function may help to defeat human cancer...
  68. ncbi request reprint Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain
    James A Thompson
    Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD 21250, USA
    Cancer Res 66:1147-54. 2006
    ..Therefore, tumor cells transduced with the CIITA, CD80, and with or without Ii siRNA present endogenously synthesized tumor antigens and are potential vaccines for activating tumor-specific CD4+ T cells...
  69. ncbi request reprint Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells
    Annemieke Dols
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA
    J Immunother 26:163-70. 2003
    ....
  70. ncbi request reprint Global role of the immune system in identifying cancer initiation and limiting disease progression
    Mary L Disis
    J Clin Oncol 23:8923-5. 2005
  71. doi request reprint An analytical workflow for investigating cytokine profiles
    Janet C Siebert
    CytoAnalytics, Analytical Services, Denver, Colorado 80209, USA
    Cytometry A 73:289-98. 2008
    ..In conclusion, the analytical workflow described herein yielded statistically supported and biologically relevant findings that were otherwise unapparent...
  72. ncbi request reprint Adoptive T cell therapy of solid cancers
    Keith L Knutson
    Mayo Clinic College of Medicine, 342D Guggenheim, 200 First St SW, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Immunol Immunother 55:96-103. 2006
    ..Some of the major problems are sources of tumor-specific T cells, ex vivo expansion, persistence, and anti-tumor activity. This review overviews the nature of these problems and some of the emerging solutions...
  73. ncbi request reprint Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals"
    Masoud H Manjili
    Department of Microbiology and Immunology, Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, 23298, USA
    Breast Cancer Res Treat 96:233-41. 2006
    ..Based on these findings, we propose to target novel antigens over-expressed in the escape variant of breast tumors to treat primary tumor and to prevent tumor relapse...
  74. ncbi request reprint Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy
    Lupe G Salazar
    J Clin Oncol 23:7397-8. 2005
  75. ncbi request reprint Molecular targeting with cancer vaccines
    Mary L Disis
    J Clin Oncol 23:4840-1. 2005
  76. ncbi request reprint IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice
    Keith L Knutson
    Department of Immunology, Mayo Clinic College of Medicine, 342C Guggenheim, 200 First Street SW, Rochester, MN 55905, USA
    J Immunol 177:84-91. 2006
    ....
  77. pmc Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides
    Holden T Maecker
    BD Biosciences, San Jose, CA, USA
    BMC Immunol 9:9. 2008
    ..Here we assess the levels of intra-assay, inter-assay, and inter-operator precision, as well as linearity, of CD8+ T cell IFNgamma-based ELISPOT and cytokine flow cytometry (CFC), as well as tetramer assays...
  78. ncbi request reprint Immunoediting of cancers may lead to epithelial to mesenchymal transition
    Keith L Knutson
    Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
    J Immunol 177:1526-33. 2006
    ..Understanding the mechanisms by which tumors are immunoedited will likely lead to a better understanding of how tumors evade immune detection...
  79. ncbi request reprint Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy
    Ulrich Keilholz
    UKBF Free University, Berlin, Germany
    J Immunother 25:97-138. 2002
    ..At present, assays appear to be most useful as measures of vaccine potency. Careful immune monitoring in association with larger scale clinical trials ultimately may enable the correlation of monitoring results with clinical benefit...
  80. pmc An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer
    Kimberly R Kalli
    Departments of Oncology, Immunology, and Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
    Cancer Res 68:4893-901. 2008
    ..All four peptides are naturally processed and presented to CD4 T-cells. The degenerate pool of peptides covers nearly 80% of patients and may be useful for augmenting CD4 T-cell immunity in patients undergoing immunization...
  81. ncbi request reprint Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature
    Margaret Inokuma
    BD Biosciences, San Jose, CA 95131, USA
    J Immunol 179:2627-33. 2007
    ..Immunotherapies directed against TAAs may need to alter these T cell signatures to be effective...
  82. pmc Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer
    Kyong Hwa Park
    Department of Internal Medicine, Division of Oncology Hematology, Korea University, Seoul, Korea
    Cancer Res 68:8400-9. 2008
    ..This is the first report of IGFBP-2 as a human tumor antigen that may be a functional therapeutic target in breast cancer...
  83. ncbi request reprint Clinical studies of vaccines targeting breast cancer
    Byung K Ko
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:3222-34. 2003
    ..The review concludes with a discussion of possible future directions for vaccine development and applications...
  84. pmc The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity
    Marshall D Behrens
    Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 111:1472-9. 2008
    ..Understanding the nature of endogenous danger signals released from dying cells may aid in a better understanding of mechanisms of immune recognition of self...
  85. pmc Immune system versus tumor: shifting the balance in favor of DCs and effective immunity
    Howard L Kaufman
    Department of Surgery, Columbia University, New York, New York 10032, USA
    J Clin Invest 113:664-7. 2004
    ....
  86. pmc Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response
    Li Xin Wang
    Center for Surgery Research, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Blood 109:4865-76. 2007
    ....
  87. ncbi request reprint Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers
    Christopher C Benz
    Buck Institute for Age Research, Novato, CA 94945, USA
    Genes Chromosomes Cancer 45:983-94. 2006
    ....
  88. ncbi request reprint 10th Biennial Helene Harris Memorial Trust meeting
    Frances R Balkwill
    Barts and The London Queen Mary s School of Medicine and Dentistry, UK
    Cancer Res 66:2904-6. 2006
    ....
  89. ncbi request reprint CD4 regulatory T cells in human cancer pathogenesis
    Keith L Knutson
    Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, 342C Guggenheim, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Immunol Immunother 56:271-85. 2007
    ..e., autoimmune disease). In this review, the biology of human CD4(+) Tregs is discussed along with their involvement in malignancies and emerging strategies to block their function...

Research Grants35

  1. HER2 VACCINATION FOR THE TREATMENT OF CANCER
    MARY DISIS; Fiscal Year: 2000
    ....
  2. Institute for Translational Health Science (UL1)
    MARY DISIS; Fiscal Year: 2007
    ..The result is a continuous process improvement that will maximize the ITHS1 ability to support and facilitate innovative translational research within and across partner institutions and the community. ..
  3. Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy.
    MARY DISIS; Fiscal Year: 2009
    ..We therefore believe that this 2 year proposal is consonant with Recovery Act goals by promoting job creation, economic development, and accelerating the pace and achievement of scientific research. ..
  4. Adoptive T Cell Therapy for the Treatment of HER2 Overexpressing Cancers
    MARY DISIS; Fiscal Year: 2009
    ..Experiments proposed will assess the magnitude of immunity achieved in vivo, the persistence of the immune response, and the potential therapeutic efficacy of the approach. ..
  5. Mechanisms of immunomodulatory and anti-tumor actions of Polysaccharide Krestin
    MARY DISIS; Fiscal Year: 2009
    ..Results from these studies will help us understand the immune modulating effect of PSK and contribute to the clinical translation of this CAM molecule as an anti-cancer agent and/or a vaccine adjuvant. ..
  6. Mechanisms of immunomodulatory and anti-tumor actions of Polysaccharide Krestin
    MARY DISIS; Fiscal Year: 2009
    ..The results generated from the revision will not only help us better understand the mechanisms of the antitumor effects of PSK, but also help us design novel PSK-based immunotherapy. ..
  7. Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy.
    MARY L contact DISIS; Fiscal Year: 2010
    ..We therefore believe that this 2 year proposal is consonant with Recovery Act goals by promoting job creation, economic development, and accelerating the pace and achievement of scientific research. ..
  8. Adoptive T Cell Therapy for the Treatment of HER2 Overexpressing Cancers
    Mary L Disis; Fiscal Year: 2010
    ..Experiments proposed will assess the magnitude of immunity achieved in vivo, the persistence of the immune response, and the potential therapeutic efficacy of the approach. ..
  9. Mechanisms of immunomodulatory and anti-tumor actions of Polysaccharide Krestin
    MARY DISIS; Fiscal Year: 2007
    ..Results from these studies will help us understand the immune modulating effect of PSK and contribute to the clinical translation of this CAM molecule as an anti-cancer agent and/or a vaccine adjuvant. ..
  10. Multi-Antigen Vaccines for Breast Cancer
    MARY DISIS; Fiscal Year: 2007
    ..abstract_text> ..
  11. Planning Grant for Institutional Clinical and Translational Science Award
    MARY DISIS; Fiscal Year: 2006
    ....
  12. HER2 VACCINATION FOR THE TREATMENT OF CANCER
    MARY DISIS; Fiscal Year: 2001
    ....
  13. HER2 VACCINATION FOR THE TREATMENT OF CANCER
    MARY DISIS; Fiscal Year: 2002
    ....
  14. Phase I Trial of a HER2 ICD Plasmid-Based DNA Vaccine
    MARY DISIS; Fiscal Year: 2003
    ..The long-term goal will be to use this study as a platform to develop multi-antigen plasmid based vaccines for the prevention of common solid tumors. ..
  15. Multi-Antigen Vaccines for Breast Cancer
    MARY DISIS; Fiscal Year: 2003
    ..abstract_text> ..
  16. HER2 VACCINATION FOR THE TREATMENT OF CANCER
    MARY DISIS; Fiscal Year: 2003
    ....
  17. Phase I Trial of a HER2 ICD Plasmid-Based DNA Vaccine
    MARY DISIS; Fiscal Year: 2004
    ..The long-term goal will be to use this study as a platform to develop multi-antigen plasmid based vaccines for the prevention of common solid tumors. ..
  18. Multi-Antigen Vaccines for Breast Cancer
    MARY DISIS; Fiscal Year: 2004
    ..abstract_text> ..
  19. MIDCAREER INVESTIGATOR AWARD IN PATIENT ORIENTED RESEARC
    MARY DISIS; Fiscal Year: 2004
    ....
  20. HER2 VACCINATION FOR THE TREATMENT OF CANCER
    MARY DISIS; Fiscal Year: 2004
    ....
  21. Phase I Trial of a HER2 ICD Plasmid-Based DNA Vaccine
    MARY DISIS; Fiscal Year: 2005
    ..The long-term goal will be to use this study as a platform to develop multi-antigen plasmid based vaccines for the prevention of common solid tumors. ..
  22. Multi-Antigen Vaccines for Breast Cancer
    MARY DISIS; Fiscal Year: 2005
    ..abstract_text> ..
  23. Immunologic Correlates of Immunization for Cancer
    MARY DISIS; Fiscal Year: 2006
    ..abstract_text> ..
  24. Phase I Trial of a HER2 ICD Plasmid-Based DNA Vaccine
    MARY DISIS; Fiscal Year: 2006
    ..The long-term goal will be to use this study as a platform to develop multi-antigen plasmid based vaccines for the prevention of common solid tumors. ..
  25. Multi-Antigen Vaccines for Breast Cancer
    MARY DISIS; Fiscal Year: 2006
    ..abstract_text> ..
  26. Phase I Trial of a HER2 ICD Plasmid-Based DNA Vaccine
    MARY DISIS; Fiscal Year: 2007
    ..The long-term goal will be to use this study as a platform to develop multi-antigen plasmid based vaccines for the prevention of common solid tumors. ..
  27. Mechanisms of immunomodulatory and anti-tumor actions of Polysaccharide Krestin
    Mary L Disis; Fiscal Year: 2010
    ..Results from these studies will help us understand the immune modulating effect of PSK and contribute to the clinical translation of this CAM molecule as an anti-cancer agent and/or a vaccine adjuvant. ..